Taltz® Alternatives

Taltz, a monoclonal antibody, has anti-inflammatory properties and can potentially alleviate symptoms of psoriasis, psoriatic arthritis, or ankylosing spondylitis. Its administration involves subcutaneous injection, and the most common side effects include injection site reactions and an elevated susceptibility to infections.

Taltz is FDA approved for the following indications: Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-Radiographic Axial Spondylarthritis.

Dupixent is an injectable medication that is typically administered subcutaneously every other week to treat inflammatory conditions, such as asthma and eczema, among others. Injection site reactions and eye conditions are the most frequently reported side effects. The risk of infection is low with Dupixent, unlike other biologics.

Dupixent is FDA approved for the following indications: Atopic Dermatitis, Asthma, Chronic Rhinosinusitis with Nasal Polyposis, Eosinophilic Esophagitis, Prurigo Nodularis.